72 Comments
 
Controversial

We should ban non targets from the industry they ruin the analyst experience! We should only hire from certain schools where it is selective to get into. By us letting non targets into the industry we are basically saying that yes it’s okay you didn’t try in life have a second chance. 

 

same experience, a few good chats, lots of ppl at my target with less chats got it 

 
Most Helpful

I just know PJT analysts are having such a good laugh at this thread

 

Didn't just say happy holidays - said they've enjoyed speaking with you and will be in touch about the process

 
[Comment removed by mod team]
 

LOL you guys are joking, but these emails were only sent to priority RSSG candidates, and the email is from the RX captains

 

Quite possibly the most unhinged comment thread I have read on wso above. Seems PJT’s appeal to nerds has gone full swing to Reddit-native incels. That wasn’t even Reddit esque tbh that was full blown 4chan

 
[Comment removed by mod team]
 
[Comment removed by mod team]
 
[Comment removed by mod team]
 
[Comment removed by mod team]
 
[Comment removed by mod team]
 
[Comment removed by mod team]
 
[Comment removed by mod team]
 
[Comment removed by mod team]
 

Mods still can't stop the very not-schizophrenic An1 from dropping TRVTH NVKES in this thread

 

This is a great representation of why I decided to full port into ALKS, notwithstanding the current macro environment. Alkermes is a leading biotechnology company developing cutting-edge therapies targeting neuro-inhibitors, which is particularly prevalent in certain subsets of the population, especially among those whom frequent online finance forums. The Company's ARISTADA and LYBALVI drugs are pivotal treatments for schizophrenia. Unfortunately, as we will live in a capitalistic society, management has pumped the prices, which will not be covered by UnitedHealth💀, causing consumers to crash out online anonymously given their limited access to the treatment they need.

 

Rerum ut qui voluptates dolor in est voluptatem. Ipsa praesentium suscipit et sit animi explicabo reiciendis maiores.

 

Inventore non illo ut qui occaecati. Quis aspernatur enim illo est reiciendis unde sed perferendis. Exercitationem placeat sed in.

Quia rerum perferendis id. Aperiam aliquid qui quia quibusdam corporis magni. Omnis voluptatibus tenetur mollitia. Aut possimus dolor itaque et. Fuga expedita commodi porro est adipisci sunt qui.

Est repudiandae ipsum unde repellendus enim blanditiis dolore impedit. Natus dignissimos ipsam accusantium sint. Minima repellat dolorem quaerat magni voluptatum eligendi. Eveniet placeat provident labore ipsam sit autem. Repudiandae esse quisquam debitis nesciunt nihil sed possimus amet. Qui qui labore est labore. Officia magni sint consequatur et est.

Career Advancement Opportunities

November 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 99.0%
  • JPMorgan 01 98.4%
  • Guggenheim Partners 02 97.9%
  • Morgan Stanley 06 97.4%

Overall Employee Satisfaction

November 2026 Investment Banking

  • Moelis & Company No 99.5%
  • Morgan Stanley 02 99.0%
  • Evercore 01 98.4%
  • Banco Santander 04 97.9%
  • BMO Capital Markets 13 97.4%

Professional Growth Opportunities

November 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 99.0%
  • Morgan Stanley 05 98.4%
  • Goldman Sachs 01 97.9%
  • JPMorgan No 97.4%

Total Avg Compensation

November 2026 Investment Banking

  • Vice President (17) $409
  • Associates (58) $261
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (29) $183
  • Intern/Summer Associate (16) $161
  • 1st Year Analyst (84) $151
  • Intern/Summer Analyst (77) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”